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Sequential administration of gemtuzumab
ozogamicin and conventional chemotherapy as
first line therapy in elderly patients with acute
myeloid leukemia: a phase II study (AML-15) of
the EORTC and GIMEMA leukemia groups
Treatment outcomes for patients withacute myeloid leukemia (AML) haveimproved substantially over the last
decade, especially for patients who are less
than 60 years of age and who are better able
to tolerate treatment regimens that include
intensive induction/consolidation chemo-
therapy and hematopoietic stem cell trans-
plantation (HSCT).1 In these patients, com-
plete remission (CR) rates of 70%–80% have
been reported. In addition, approximately
40% of patients younger than 60 years of
age have prolonged disease-free survival of
5 years.2,3 In contrast, older patients with AML
have CR rates of 40%–60% with conven-
tional chemotherapy and disease-free sur-
vival of less than 20% at 3 years.4-6 Since
more than 50% of AML cases occur in
patients over 60 years old, treatment of old-
er patients with AML remains a therapeutic
challenge.7 Most patients in this age group
are less able to tolerate the intensive chemo-
therapy regimens associated with higher
remission rates, have pre-existing hemato-
logic disorders, and are more likely to have a
higher incidence of poor-risk cytogenetic
abnormalities or expression of the multidrug
resistance phenotype.7-9
Gemtuzumab ozogamicin (GO) is an
immunoconjugate that has shown promis-
ing activity in relapsed AML.10-12 It is com-
posed of a humanized anti-CD33 antibody
linked to the potent antitumor antibiotic
calicheamicin and provides a novel method
of drug delivery by using the monoclonal
antibody to target CD33+ leukemic cells.13-17
CD33 is an antigen expressed during myeloid
cell differentiation and is found on the sur-
face of leukemic blasts in >90% of AML cas-
es, but is not present on normal hematopoi-
etic stem cells or, with few exceptions, on
normal tissues.18 By targeting cells that only
Background and Objectives. Acute myeloid leukemia (AML) in the elderly is associ-
ated with low rates of response to conventional chemotherapy and long-term survival,
highlighting the need for innovative treatment strategies. Gemtuzumab ozogamicin
(GO) is an immunoconjugate that has shown activity in relapsed AML with a favorable
safety profile. The aim of this collaborative trial was to assess the feasibility, safety, and
antileukemic activity of administering GO followed by conventional chemotherapy as
first line therapy in patients aged 61–75 years with AML. 
Design and Methods. Eligible patients received frontline treatment with GO 9 mg/m2
infused intravenously on days 1 and 15.  Following response assessment to GO, patients
were started on conventional chemotherapy consisting of the MICE regimen (mitox-
antrone, cytarabine, etoposide). No further treatment was planned for complete respon-
ders.
Results. Among the 57 evaluable patients, 38 (67%) completed the entire sequential
treatment as planned. The overall response rate to the entire induction sequence was
54.4% (31/57), with complete remission (CR) in 35.1% and complete remission with
incomplete platelet recovery (CRp) in 19.3%. Rates of failure due to treatment-relat-
ed mortality or resistant disease were 14.1% (3 toxic deaths during the GO segment, 5
during MICE) and 29.9%, respectively. An initial response to GO was documented in 20
patients (35.1%), with CR in 22.8% and CRp in 12.3%; 6 additional patients entered a
partial remission. Reversible myelosuppression and liver toxicity were the main adverse
events during both segments of induction. Frontline GO was associated with modest
mucosal and gastrointestinal toxicity, but grade 3-4 pancytopenia was universal and
prolonged. Hepatic veno-occlusive disease developed in 3 patients after GO and 2 after
MICE, resulting in 4 deaths from liver failure. One-year survival at follow-up was 34%.
Twelve patients continue in CR/CRp after a median of 226 days. 
Interpretation and Conclusions. The sequential combination of GO and convention-
al chemotherapy is a feasible and active treatment strategy for older patients with
untreated AML. This novel regimen is now being compared in a phase III trial (AML-17).
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express this antigen, GO is able to eliminate the leukemic
blasts from the marrow and blood without many of the
systemic toxicities associated with traditional
chemotherapeutic agents.12,19-20 In combined  phase II
studies of 142 patients with AML in first relapse, GO
monotherapy (two doses of 9 mg/m2 given 14 days
apart) was associated with a 30% overall complete
remission rate, including a 26% response rate in patients
over 60 years of age.11,21 Although myelosuppression and
reversible increases in levels of serum bilirubin and
transaminases were commonly observed, severe mucosi-
tis and grade 3-4 infections were not. These results led
to the recent US Food and Drug Administration approval
of GO for the treatment of patients over 60 years of age
with relapsed AML.22 As a consequence of these encour-
aging early results, interest in extending the use of GO
to frontline treatment of AML in combination with con-
ventional chemotherapy, in particular as a means of
improving the quality of induced remissions, has
increased.23 When applied to younger patients with pre-
viously untreated AML, this combination strategy
appears reasonably well tolerated and associated with
promising rates of initial response.24-25
To get more insights into the feasibility of such a com-
bined approach, the EORTC Leukemia Group (EORTC-LG),
in collaboration with the Italian Cooperative Group
GIMEMA, conducted a phase II study of GO and con-
ventional chemotherapy with mitoxantrone, cytarabine,
and etoposide (the MICE regimen) for induction of
remission in previously untreated AML patients aged 61
to 75 years old. A sequential scheduling design was
selected for this combination trial for the following two
reasons: (i) to assess the toxicity and antileukemic activ-
ity of single agent GO when given frontline in previous-
ly untreated AML; (ii) to minimize the risk of additive
acute toxicity potentially resulting from the two regi-
mens given concurrently.
Design and Methods
Patients
Patients 61–75 years of age with previously untreat-
ed AML and who had a World Health Organization
(WHO) performance status (PS) of grade 0 to 1 were
allowed to participate in the study. Patients were
required to have previously untreated primary or sec-
ondary AML (including AML after myelodysplastic syn-
drome) with a diagnostic bone marrow containing at
least 20% leukemic blasts according to the recently
developed WHO criteria.25 Patients were excluded from
the study if they had previously received treatment for
their AML with other cytotoxic agents (except hydroxy-
urea for no more than 7 days and/or corticosteroids) or
if they had acute promyelocytic leukemia (FAB M3), blast
crisis of chronic myeloid leukemia, or leukemia super-
vening after other myeloproliferative diseases. In addi-
tion, patients with active central nervous system (CNS)
leukemia, concomitant progressive malignant disease,
active uncontrolled infection, or inadequate renal or liv-
er function (i.e. creatinine or bilirubin > 3 times the
upper limit of normal) were not allowed to participate
in the study.
Although not a requirement for entry into the trial,
CD33 expression was evaluated locally by immunophe-
notyping leukemic blasts at diagnosis in all patients with
adequate samples of bone marrow aspirates. If 20% or
more of marrow blasts expressed the CD33 antigen, the
patient was considered to have CD33+ AML. Cytogenet-
ic studies on pretreatment bone marrow were performed
locally according to standard protocols. Centrally
reviewed karyotypes were interpreted using the Inter-
national System for Cytogenetic Nomenclature (ISCN)
criteria.26 Risk groups were defined as follows: the favor-
able-risk group included patients with t(8;21) or chro-
mosome 16 abnormalities; the unfavorable-risk group
included patients with abnormalities of chromosome 5
and 7 (-5/5q-, -7/7q-) or complex karyotypes (>3 abnor-
malities); the intermediate-risk group included patients
with normal cytogenetics or –Y alone; and all other
abnormalities were lumped together in the other-risk
group. The patients with unknown, not done, or unsuc-
cessful cytogenetics were included in the unknown-risk
group.
This study was approved by the European Organization
for the Research and Treatment of Cancer (EORTC) Pro-
tocol Review Committee and by the Ethical Committee
of each participating institution. Written, informed con-
sent according to ICH/EU GCP, and national/local regu-
lations was obtained from each patient before partici-
pation.
Treatment
Patients received frontline GO at the FDA-approved
dose/schedule of 9 mg/m2 as a single 2-hour IV infusion
on days 1 and 15. The second dose was given, irrespec-
tive of the peripheral blood status, if patients had recov-
ered from non-hematologic toxicities resulting from the
previous injection and had no evidence of uncontrolled
infection or disease progression, but no more than 28
days were allowed between doses. Patients were rou-
tinely premedicated with acetaminophen and antihist-
amines to prevent or reduce infusion reactions. Bone
marrow aspirates were obtained on day 14 for assess-
ment of cellularity and 28 days following the last GO
dose for assessment of response. Within 7–10 days of
response assessment and regardless of the type of
response achieved after GO, patients began conventional
chemotherapy consisting of the MICE regimen:  mitox-
antrone 7 mg/m2/day as a 30-min IV infusion on days 1,
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3, and 5 (3 doses), etoposide 100 mg/m2/day as a 1-hr
IV infusion on days 1–3 (3 doses), and cytarabine 100
mg/m2/day as a continuous IV infusion on days 1–7. No
postremission therapy was planned for patients achiev-
ing complete remission unless decided otherwise by the
treating physicians.
Response criteria
The primary efficacy end point in this study was the
rate of complete remission induced by the sequential
administration of GO and MICE chemotherapy; second-
ary end points included the rate of response to frontline
GO, disease-free survival (DFS) and overall survival (OS).
Complete remission (CR) was defined by the bone mar-
row being shown to contain fewer than 5% blast cells,
a cellularity of at least 20% with maturation of all cell
lines, an absence of Auer rods and of extramedullary
leukemia, and a blood smear free of leukemic blasts. The
absolute neutrophil count had to be at least 1.5×109/L,
and the platelet count greater than 100×109/L. On the
basis of the phase I/II clinical results indicating that in
some responders to GO a delay in platelet recovery may
occur, the additional category of CRp was introduced.10-
11 Patients with CRp met all CR parameters with the
exception of full platelet recovery, while remaining
platelet transfusion independent. Partial remission (PR)
was defined as 5%–10% blasts or < 5% blasts in the
presence of Auer rods in a bone marrow of adequate
cellularity, with a blood smear without leukemic blasts.
Treatment failure was defined by failure to achieve CR,
CRp, or PR. Relapse following CR/CRp was defined as
reappearance of blasts in the blood or the finding of
more than 5% blast cells in the bone marrow that were
not attributable to another cause such as marrow regen-
eration.
Toxicity criteria
All toxicities reported during therapy were evaluated
according to the National Cancer Institute Common Tox-
icity Criteria (CTC-NCI, version 2.0).
Statistical methods
All patients were registered prospectively at the EORTC
Data Center in Brussels. The duration of survival was
calculated from the date of start of treatment until the
date of death from whatever cause. For patients achiev-
ing CR/CRp after induction, DFS was calculated from
the date of remission until the date of relapse or death
in CR/CRp. Actuarial curves were computed using the
Kaplan-Meier technique, and the standard errors of the
estimates were obtained from Greenwood’s formula. An
intent-to-treat analysis was used; all eligible patients
who started frontline GO were included for the evalua-
tion of remission rate and OS. The CR/CRp rate and the
95% confidence interval were computed. The associa-
tion of baseline characteristics with response outcome
was examined using Kendall’s τ test. The cut-off date for
the statistical analyses was November 30, 2002. SAS 8.1
statistical software was used.
Results
Patients’ characteristics
From 09/2000 to 10/2001, 64 consecutive patients
fulfilling the eligibility criteria from 15 institutions were
enrolled into this study. Four patients were found to be
not eligible either because of a WHO performance sta-
tus > 1 (2 patients) or the presence of severe comorbid
conditions (2 patients). Among the remaining 60
patients, 3 withdrew consent before starting treatment
thus leaving a total of 57 patients evaluable for response
and toxicity. 
Demographics and baseline characteristics of the 57
evaluable patients are shown in Table 1. The median age
was 68 years (range, 61–73 years), 40 patients were
male, and 43 had primary AML. CD33 positivity on bone
marrow blasts was documented in 84.6% of the 52
patients for whom immunophenotyping data were avail-
able. Cytogenetic data were evaluable in 40/57 patients
(70%): 20 (35%) and 9 (16%) were classified in the
intermediate and the unfavorable-risk group categories,
respectively; 11 (19%) patients had other chromosomal
abnormalities and none had a favorable karyotype.
Treatment outcome
Of the 57 patients who were started on GO, 47 (82%)
received the scheduled second injection. The primary
reasons 10 patients did not receive the second dose were
disease progression (4 patients: 2 died rapidly of
leukemia-related complications, and 2 were switched
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Table 1. Baseline characteristics of the study group (n =
57).
Median age (yrs) 68 (range 61–73)
Male/female 40/17
Performance status 0/1 21/36
Primary/secondary AML 43/14
FAB subtype
M0/M1/M2 4/8/28
M4/M5/M6/unknown 3/5/4/5
Cytogenetic risk group
Intermediate 20
Other 11
Unfavorable 9
Unknown 17
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to immediate MICE), early death (2 patients), toxicity (2
patients: 1 infection, 1 liver dysfunction), and protocol
violations (2 patients). The rate of initial response to GO
was 35.1% (95% CI, 22.9%–48.9%) with 13 CR and 7
CRp, as listed in Table 2; 6 additional patients achieved
PR (10.5%). Of the remaining 31 patients, 3 (5.3%) died
of toxicity, and 28 were resistant. Altogether, 51 patients
survived GO therapy and 38 of them (75%) were given
one course of the MICE regimen after a median interval
of 49.5 days (range 12–77 days) from the first GO injec-
tion. Reasons for not starting MICE included excessive
toxicity (11 patients: 8 infection, 3 liver dysfunction),
refusal (1 patient), and protocol violation (1 patient).
Response to the induction sequence is shown in Table
2. The overall complete remission rate (ORR) was 54.4%
(31/57; 95% CI, 40.7%–67.6%). The CR and CRp rates
were 35.1% and 19.3%, respectively. One patient (1.8%)
achieved PR, and 17 (29.9%) had resistant disease. Five
patients died of complications during the MICE segment,
for an overall treatment-related mortality of 14.1%
(8/57). MICE chemotherapy substantially improved over-
all response. Among the 19 evaluable patients whose
disease failed to respond initially to GO, the addition of
MICE was effective in achieving remission in 10 (53%),
inducing a CR in 7 and a CRp in 3. Of the 57 patients
enrolled in this trial, 33 have died. With a median fol-
low-up of 12 months, the estimated probability of sur-
vival at 1 year was 34% (SE = 7.2%) (Figure 1). Leukemia
recurred between 39 and 372 days in 18 of the 31
patients who had CR/CRp, and 1 additional patient died
in CRp on day 18. The median DFS was 190 days, and
was similar for both CR and CRp patients.
Safety and tolerability
As expected, severe myelosuppression was universal-
ly seen during both segments of the sequential induc-
tion program. In particular, grade 3-4 neutropenia and
thrombocytopenia were quite prolonged after GO with
complete responders requiring a median of 37 and 32
days from the first infusion to recover neutrophil and
platelet counts > 500/µL and > 50,000/µL, respective-
ly. Hematopoietic recovery post-MICE was not compro-
mised by previous exposure to GO as indicated by the
fact that the number of days to recover neutrophil and
platelet counts was fully comparable with those of an
historical group of patients treated with MICE alone
(median of 24 days for both). Additional grade 3-4 tox-
icities that occurred during therapy are shown in Table
3. The most common non-hematologic adverse events
reported during GO therapy included infusion-related
allergic reaction (1.8%), hypertension (3.6%), hypoten-
sion (3.6%), hemorrhage (3.6%), renal dysfunction
(5.3%), elevated SGPT (5.3%) and bilirubin (8.8%), infec-
tion (28%), and febrile neutropenia (40.4%). Of note,
mucositis-related side effects (stomatitis, diarrhea) were
unusual: only 1.8% of patients experienced severe gas-
trointestinal toxicity during this segment. As expected,
severe mucositis occurred more frequently during MICE
(5.3%) and was associated with the usual cohort of
grade 3-4 adverse events typically seen during conven-
tional chemotherapy, such as hemorrhage (13.1%),
hyperbilirubinemia (13.1%), infection (31.6%), and
febrile neutropenia (36.8%). Signs and symptoms sug-
gestive of hepatic veno-occlusive disease (VOD) were
observed in a total of 5 patients, of whom 4 died of liv-
er failure. Three cases of VOD occurred during therapy
with GO: 1 patient died 9 days after the first infusion, 1
patient died 20 days after the second dose right after a
CRp status had been documented, 1 patient developed
VOD 20 days after the second dose and recovered. Two
episodes of VOD occurred following MICE (after 10 and
21 days), and both were fatal: neither of the two patients
Table 2. Response to therapy.
After GO Overall
n (%) n (%)
CR 13 (22.8) 20 (35.1)
CRp 7 (12.3) 11 (19.3)
CR+CRp 20 (35.1) 31 (54.4)
PR 6 (10.5) 1 (1.8)
Failure 28 (49.1) 17 (29.9)
Toxic death 3 (5.3) 8 (14.1)
Number of patients at risk
32 11 1
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Figure 1. Overall survival from start of therapy.
 
had evidence of grade 3-4 liver dysfunction during the
preceding GO segment. Overall, the mortality rate for
the entire induction program was 14.1% (8/57). A total
of 3 patients died during GO therapy, one each of acute
respiratory distress syndrome, infection, and VOD. The
causes of the 5 toxic deaths which occurred during MICE
were infection (n=1), heart failure (n=1), multi-organ
failure (n=1), and VOD (n=2).
Prognosis by pre-treatment characteristics
Baseline characteristics including age, type of AML,
WBC count, and marrow blastosis were not predictive of
treatment outcome in this study. Furthermore, the
CR/CRp rate after GO was apparently not influenced by
CD33 positivity (15/44 with CD33+ AML, 34%; 3/8 with
CD33− AML, 37.5%; Kendall’s τ = -0.13, p = 0.39),
although patients with a high degree of CD33 expres-
sion (> 80% positive blasts) tended to respond more
favorably to the immunoconjugate (7/14, 50%) com-
pared to those expressing the antigen in 20–80% of
blasts (8/30, 26.7%). The impact of cytogenetics on ini-
tial response to GO was of borderline significance
(Kendall’s τ = 0.29, p = 0.057): 9 of 20 patients with an
intermediate-risk karyotype achieved CR/CRp versus 3 of
11 and 1 of 9 in the other-risk and the unfavorable-risk
group, respectively; the rate of response in the
unknown-risk group was 7 of 17. Cytogenetics, howev-
er, became highly influential (Kendall’s τ = 0.49, p =
0.004) when response to the entire induction sequence
was considered: CR/CRp was achieved by 15 of 20 with
intermediate-risk, 4 of 11 in the other-risk cytogenetic
group, 2 of 9 in the unfavorable-risk group and 10 of 17
in the unknown-risk group.
Discussion
Treatment of AML in the elderly continues to be a con-
troversial issue and there is little doubt that conven-
tional chemotherapy with curative intent is generally
applied only to a minority of medically fit patients
selected on the basis of age and performance status.
However, the outcome of these patients following inten-
sive treatment strategies has remained disappointing
with CR rates around 50%, induction death rates of 15%
to 30%, a relapse risk in complete responders in excess
of 80% and a 3-year survival rate of less than 20%.2,7-8
In the recently completed EORTC-LG/GIMEMA AML-13
trial, out of a total of 722 registered patients (median
age 68 years; range, 60–80 years) with previously
untreated AML, 697 were assessable for response to
conventional induction chemotherapy. After 1 or 2
courses of MICE, CR was achieved in 382 (54.8%) and
the toxic mortality rate during induction was 14.2%.
With a median follow-up of 3.9 years, 3-year estimates
of DFS and OS were 18.8% and 17%, respectively. Thus,
there is a need to identify innovative treatment strate-
gies and/or new antileukemic agents that are more
effective and less toxic in older patients with AML. Giv-
en its tolerability and encouraging activity in relapsed
AML, trials of GO combined with conventional chemo-
therapy in older patients with untreated AML appear
reasonable. Arguably, the use of a drug that targets AML
blasts more specifically could result in a better
antileukemic control when combined with convention-
al regimens, without adding excessive extramedullary
toxicity.  
The results of this study indicate that the sequential
administration of GO and conventional chemotherapy is
a feasible strategy for first line therapy in elderly patients
with AML, resulting in complete response (CR+CRp,
54.4%) and survival rates (34% at 1 year) comparable
to those currently achievable with conventional regi-
mens.5,8,27 Furthermore, remission duration in this study
appears promising compared with that obtained in the
previous AML-13 trial, in which two additional courses
of myelosuppressive chemotherapy were routinely
administered as consolidation in complete responders.
This latter finding is suggestive of a synergistic interac-
tion between GO and conventional chemotherapy in
increasing the depth of leukemia cytoreduction, thus
raising hopes that this novel regimen may improve the
outcome of patients with this disease by enhancing the
quality of the remissions induced. Thirty-eight of the 57
evaluable patients who received the first infusion of GO
were able to complete the MICE segment of induction
for an overall feasibility rate of 67%. Completion of the
entire induction sequence was of clinical relevance as
shown by the fact that out of the 19 evaluable patients
whose leukemia was refractory to GO, 10 achieved com-
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Table 3. Most common grade 3 to 4 non-hematologic tox-
icities.
After GO After MICE
(n = 57) (n = 38)
Allergy 1.8 0
Hypertension 3.6 2.6
Hypotension 3.6 0
Nausea 5.3 5.2
Diarrhea 1.8 2.6
Stomatitis 0 5.3
Hemorrhage 3.6 13.1
Febrile neutropenia 40.4 36.8
Infection 28.1 31.6
Elevated creatinine 5.3 2.6
Elevated total bilirubin 8.8 13.1
Elevated transaminases 5.3 2.6
Hepatic VOD 5.3 5.3
Values expressed as % of evaluable patients.
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plete remission (7 CR, 3 CRp) following MICE, suggest-
ing a lack of cross-resistance to the two regimens.
Taking advantage of the sequential design of this com-
bination trial, we were able to get information on the
safety and antileukemic activity of GO as frontline
monotherapy in elderly patients with untreated AML. By
inducing CR/CRp in 35.1% of patients, the targeted drug
proved to be one of the most effective single agents cur-
rently available in this setting. Furthermore, the
antileukemic activity of the drug was apparently not
influenced by presenting features such as age, type of
disease, WBC count, and degree of marrow blastosis.
However, due to the limited number of patients includ-
ed in this study, no conclusion can be drawn in this
respect.
Although a positive correlation between initial
response to GO and degree of CD33 expression was
apparent, the relationship was not absolute as indicat-
ed by the fact that 3 of the 8 patients (37.5%) with so-
called CD33− AML did enter complete remission follow-
ing GO. Apart from the obvious consideration that the
low predictive value of CD33 expression may just be an
artifact reflecting a certain degree of heterogeneity in
the level of sensitivity of the standard flow cytometric
technique in use at the participating institutions, the
possibility that additional CD33-independent cytotoxic-
ity might be induced by GO must be considered, espe-
cially in light of recent observations made by Jedema
and colleagues indicating that the drug is in fact able to
exert a cell killing effect against several CD33− lymphoid
cell lines via a non-specific phagocytosis of the immuno-
conjugate.28
As expected, adverse cytogenetics was associated with
a significantly lower overall response rate to the entire
induction program. Such an inferior treatment outcome
was already apparent following GO, although the trend
was of marginal significance, thus supporting the con-
cept that the high prevalence of a chemoresistant phe-
notype and unfavorable cytogenetics, typically associat-
ed with advanced age, may likely contribute to a poorer
clinical response to the targeted drug.9,29 In this regard, a
recent study of relapsed AML patients undergoing
monotherapy with GO showed that expression of the P-
glycoprotein (P-gp) by the leukemic blasts was associat-
ed with a worse clinical outcome.29 Furthermore, in vitro
resistance to the immunoconjugate in P-gp expressing
cell lines and primary AML blasts can be overcome by P-
gp inhibitors such as cyclosporine, suggesting that com-
bined treatment with reversal agents might improve
response to GO.30 The toxicity observed with this sequen-
tial treatment strategy was generally manageable, sup-
porting early clinical data indicating that the safety pro-
file of GO is in fact somewhat different from that
observed with conventional chemotherapy.12 Hemato-
logic and hepatic toxicity were the main adverse events
observed throughout the whole induction period. Myelo-
suppression was universal and profound after each seg-
ment of the induction program, but interestingly grade
3-4 neutropenia and thrombocytopenia were more pro-
longed after GO than following MICE chemotherapy, sug-
gesting that prior exposure to the targeted drug does
not compromise the ultimate regenerative potential of
the bone marrow in these patients. Total duration of
cytopenias was on average in excess of 50 days for
patients completing both segments of the induction
sequence, but this rather prolonged period of myelosup-
pression was not associated with an increased risk of
dying from toxicity as indicated by an overall induction
mortality rate of 14.1%, similar to that observed in the
previous AML-13 trial in which only MICE chemothera-
py was employed for remission induction. Thus, the
extended myelotoxicity associated with the administra-
tion of GO followed by MICE chemotherapy may likely
result in a more profound antileukemic effect without
increasing the therapeutic risk in older patients with
AML. Based on pharmacokinetic data indicating a satis-
factory degree of saturation of CD33 binding sites when
a dose of 6 mg/m2 was infused,10 we speculate that low-
er doses of GO may prove as effective and less myelotoxic
in these conditions, thus allowing a higher proportion of
patients to reach the MICE segment of the induction
sequence. Such dose-reduction should also result in a
lower incidence of severe clinical hepatotoxicity, a rec-
ognized and potentially fatal side-effect associated with
the administration of GO at full doses.
This issue is now being investigated in the current
AML-17 phase III trial, which was designed to prospec-
tively address the comparative benefits of lower doses of
GO combined with sequential chemotherapy versus
chemotherapy alone in patients 61–75 years old with
untreated AML.
SA was the principal investigator; SA, RW, FM and TDW conceived
and designed the study; FB, OA and MV were responsible for collec-
tion and management of the data; AH was responsible for central
review of cytogenetic data; SS was responsible for the statistical
analysis. SA, RW, FM, DS, RS, AH, CD, GL, PF, and PM were responsible
for the clinical care of patients at the participating centers. The final
manuscript was written by SA and critically revised and approved by
all the remaining authors. The authors reported no potential conflicts
of interest.
This work was supported in part by grants from Wyeth Pharma-
ceuticals and the National Cancer Institute (grant numbers 5U10-
CA11488-29 through 5U10-CA11488-32). Its contents are solely the
responsibility of the authors and do not represent the official views of
the National Cancer Institute (Bethesda, Maryland, USA).
We wish to thank Dr. Jay Feingold for his advice and support.
Manuscript received May 7, 2004. Accepted June 9, 2004.
 
haematologica 2004; 89(8):August 2004956
S. Amadori et al.
References
1. Zittoun RA, Mandelli F, Willemze R, De
Witte T, Labar B, Resegotti L, et al. Autol-
ogous or allogeneic bone marrow trans-
plantation compared with intensive
chemotherapy in acute myelogenous
leukemia. N Engl J Med 1995;332:217-23.
2. Lowenberg B, Downing JR, Burnett AK.
Acute myeloid leukemia. N Engl J Med
1999;341:1051-62.
3. Burnett AK. Acute myeloid leukemia:
treatment of adults under 60 years. Rev
Clin Exp Hematol 2002; 6: 26-45. 
4. Latagliata R, Petti MC, Mandelli F. Acute
myeloid leukemia in the elderly: 'per
aspera ad astra'? Leuk Res 1999;23:603-
13.
5. Lowenberg B, Suciu S, Archimbaud E,
Haak H, Stryckmans P, de Cataldo R, et al.
Mitoxantrone versus daunorubicin in
induction-consolidation chemothera-
py–the value of low-dose cytarabine for
maintenance of remission, and an assess-
ment of prognostic factors in acute
myeloid leukemia in the elderly: final
report. European Organization for the
Research and Treatment of Cancer and
the Dutch-Belgian Hemato-Oncology
Cooperative Hovon Group. J Clin Oncol
1998;16:872-81.
6. Estey EH. How I treat older patients with
AML. Blood 2000; 96:1670-3.
7. Stasi R, Venditti A, Del Poeta G, Aronica G,
Dentamaro T, Cecconi M, et al. Intensive
treatment of patients age 60 years and
older with de novo acute myeloid
leukemia: analysis of prognostic factors.
Cancer 1996;77:2476-88.
8. Hiddemann W, Kern W, Schoch C, Fo-
natsch C, Heinecke A, Wormann B, et al.
Management of acute myeloid leukemia
in elderly patients. J Clin Oncol 1999; 17:
3569-76.
9. Leith CP, Kopecky KJ, Godwin J,
McConnell T, Slovak ML, Chen IM, et al.
Acute myeloid leukemia in the elderly:
assessment of multidrug resistance
(MDR1) and cytogenetics distinguishes
biologic subgroups with remarkably dis-
tinct responses to standard chemothera-
py. Blood 1997;89:3323-9.
10. Sievers EL, Appelbaum FR, Spielberger RT,
et al. Selective ablation of acute myeloid
leukemia using antibody-targeted chemo-
therapy: a phase I study of an anti-CD33
calicheamicin immunoconjugate. Blood
1999;93:3678-84. 
11. Sievers EL, Larson RA, Stadtmauer EA,
Forman SJ, Flowers D, Smith FO, et al.
Efficacy and safety of gemtuzumab ozo-
gamicin in patients with CD33-positive
acute myeloid leukemia in first relapse. J
Clin Oncol 2001;19:3244-54.
12. McGavin JK, Spencer CM Gemtuzumab
ozogamicin. Drugs 2001;61:1317-22.
13. van Der Velden VHJ, te Marvelde JG,
Hoogeveen PG, Bernstein ID, Houtsmuller
AB, Berger MS, et al. Targeting of the
CD33-calicheamicin immunoconjugate
Mylotarg (CMA-676) in acute myeloid
leukemia: in vivo and in vitro saturation
and internalization by leukemic and nor-
mal myeloid cells. Blood 2001;97:3197-
204.
14. Rabasseda X, Graul A, Castaner RM. Gem-
tuzumab ozogamicin: treatment of acute
myeloid leukemia. Drugs Fut 2000; 25:
686-92.
15. Zein N, Sinha AM, McGahren WJ, Ellestad
GA. Calicheamicin γ1I: an antitumor
antibiotic that cleaves double-stranded
DNA site specifically. Science 1988; 240:
1198-201.
16. Scheinberg DA, Lovett D, Divgi CR, Gra-
ham MC, Berman E, Pentlow K, et al. A
phase I trial of monoclonal antibody
M195 in acute myelogenous leukemia:
specific bone marrow targeting and inter-
nalization of radionuclide. J Clin Oncol
1991;9:478-90.
17. Appelbaum FR, Matthews DC, Eary JF,
Badger CC, Kellogg M, Press OW, et al.
The use of radiolabeled anti-CD33 anti-
body to augment marrow irradiation pri-
or to marrow transplantation for acute
myelogenous leukemia. Transplantation
1992;54:829-33.
18. Legrand O, Perrot JY, Baudard M, Cordier
A, Lautier R, Simonin G, et al. The immu-
nophenotype of 177 adults with acute
myeloid leukemia: proposal of a prognos-
tic score. Blood 2000;96:870-7.
19. Treish IM. Targeting leukemia cells with
gemtuzumab ozogamicin. Cancer Pract
2000;8:254-7.
20. Sievers EL. Targeted therapy of acute
myeloid leukemia with monoclonal anti-
bodies and immunoconjugates. Cancer
Chemother Pharmacol 2000;46 Suppl
1:S18-S22.
21. Larson RA, Boogaerts M, Estey E, Karanes
C, Stadtmauer EA, Sievers EL, et al. Anti-
body-targeted chemotherapy of older
patients with acute myeloid leukemia in
first relapse using Mylotarg (gemtuzum-
ab ozogamicin). Leukemia 2002;16:1627-
36.
22. Bross PF, Beitz J, Chen G, Chen XH, Duffy
E, Kieffer L, et al. Approval summary:
gemtuzumab ozogamicin in relapsed
acute myeloid leukemia. Clin Cancer Res
2001;7:1490-6.
23. Larson RA. Current use and future devel-
opment of gemtuzumab ozogamicin.
Semin Hematol 2001;38:24-31.
24. Kell WJ, Burnett AK, Chopra R, Yin JA,
Clark RE, Rohatiner A, et al. A feasibility
study of simultaneous administration of
gemtuzumab ozogamicin with intensive
chemotherapy in induction and consoli-
dation in younger patients with acute
myeloid leukemia. Blood 2003;102:4277-
83. 
25. De Angelo D, Schiffer C, Stone R, Amrein
P, Fernandez H, Bradstock K, et al. Inter-
im analysis of a phase II study of the safe-
ty and efficacy of gentuzumab ozogam-
icin (Mylotarg) given in combination with
cytarabine and daunorubicin in patients
<60 years old with untreated acute
myeloid leukemia. Blood 2002; 100 Sup-
pl 1:198a[abstract].
25. Harris NL, Jaffe ES, Diebold J, Flandrin G,
Muller-Hermelink HK, Vardiman J, et al.
World Health Organization classification
of neoplastic diseases of hematopoietic
and lymphoid tissue: report of the clini-
cal advisory committee meeting. J Clin
Oncol 1999;17:3835-49.
26. Mitelman F. ISCN: an international sys-
tem for human cytogenetic nomencla-
ture. Basel; S. Karger. 1995.
27. Goldstone AH, Burnett AK, Wheatley K,
Smith AG, Hutchinson M, Clark RE.
Attempts to improve treatment outcomes
in acute myeloid leukemia (AML) in old-
er patients: the results of the United
Kingdom Medical Research Council AML
11 trial. On behalf of the Medical
Research Council Adult Leukaemia Work-
ing Party. Blood 2001;98:1302-11.
28. Jedema I, Barge RMY, van Der Velden VHJ,
te Marvelde JG, van Dongen JJM,
Willemze R, et al. Internalization and cell
cycle dependent killing of leukemic cells
by gemtuzumab ozogamicin: rationale for
clinical application of Mylotarg® in CD33
negative malignancies with phagocytot-
ic capacity. Blood 2002; 100 Suppl 1:
340a[abstract].
29. Naito K, Takeshita A, Shigeno K, Naka-
mura S, Fujisawa S, Shinjo K, et al. Cali-
cheamicin-conjugated humanized anti-
CD33 monoclonal antibody (gemtuzum-
ab ozogamicin, CMA-676) shows cytoci-
dal effect on CD33-positive leukemia cell
lines, but is inactive on P-glycoprotein-
expressing sublines. Leukemia 2000; 14:
1436-43.
30. Linenberger ML, Hong T, Flowers D, Siev-
ers EL, Gooley TA, Bennett JM, et al. Mul-
tidrug-resistance phenotype and clinical
responses to gemtuzumab ozogamicin.
Blood 2001;98:988-94.
